“NAD+ biology research holds the key to understanding age-related declines and diseases,” said Dr. Richard H. Kaszynski, MD. “Our collaboration with EffePharm aims to pioneer advancements in this crucial field, driving transformative results in wellness and longevity. Current studies on NMNH demonstrate great potential, positioning it as the next-generation NAD+ booster. I am incredibly excited about EffePharm’s ongoing phase I clinical study on UthPeak™ NMNH, which promises groundbreaking advancements in preventive medicine and age-related disease intervention.”
At EffePharm, the company is committed to providing scientifically backed solutions for enhanced wellness and anti-aging benefits. EffePharm is proud of the groundbreaking clinical trial on UTHEVER®, the world’s first clinically proven NMN brand. The journey continues with UthPeak™ NMNH. UthPeak™ NMNH has gone through rigorous toxicology testing and efficacy testing, paving the way for its current phase I clinical study.
Dr. Kaszynski’s extensive expertise and research background will be invaluable as EffePharm pursues its mission to empower individuals with cutting-edge wellness solutions. His contributions will undoubtedly enhance EffePharm’s efforts to deliver products that are not only effective but also backed by strong scientific evidence.
For media inquiries or further information, please contact EffePharm Marketing marketing@effepharm.com.